Physician profile
Umar Daud
NPI 1053388942
$4,945.53
in general payments reported to CMS, 2019-2025
20 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $528 · 2021: $1,115 · 2022: $1,219 · 2023: $1,134 · 2024: $391 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.07 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.56 | 2020-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $668.17 | 2019-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $596.21 | 2020-2024 | |
| Pfizer INC. | $492.68 | 2019-2025 | |
| Amgen INC. | $481.98 | 2019-2025 | Uplizna, Otezla, Enbrel |
| Ucb, INC. | $363.58 | 2020-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $312.62 | 2021-2023 | Taltz, Olumiant |
| Astrazeneca Pharmaceuticals LP | $253.58 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $248.91 | 2020-2021 | |
| Glaxosmithkline, LLC. | $160.51 | 2021-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $71.90 | 2021-2023 | Actemra |
| Genzyme Corporation | $55.29 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.19 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.51 | 2023 | Cyltezo |
| Teva Pharmaceuticals USA, INC. | $30.99 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $29.10 | 2021-2022 | |
| Organon LLC | $26.05 | 2023 | Renflexis, Hadlima |
| Alexion Pharmaceuticals, INC. | $14.29 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.43 | 2019 | |
| Celgene Corporation | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umar Daud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.